Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Methotrexate | hsa00030 | Pentose phosphate pathway | 6.21E-04 | 3 | P52209, P11413, P37837 | PGD, G6PD, TALDO1 | More | | Methotrexate | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Methotrexate | hsa00190 | Oxidative phosphorylation | 3.27E-02 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | Methotrexate | hsa00230 | Purine metabolism | 4.02E-02 | 2 | P31350, P21589 | RRM2, NT5E | More | | Methotrexate | hsa00240 | Pyrimidine metabolism | 2.54E-04 | 3 | P31350, P21589, P04818 | RRM2, NT5E, TYMS | More | | Methotrexate | hsa00280 | Valine, leucine and isoleucine degradation | 2.75E-02 | 4 | P55809, Q9HCC0, Q02252, P11310 | OXCT1, MCCC2, ALDH6A1, ACADM | More | | Methotrexate | hsa00310 | Lysine degradation | 2.59E-02 | 2 | Q96KQ7, P51648 | EHMT2, ALDH3A2 | More | | Methotrexate | hsa00480 | Glutathione metabolism | 1.35E-02 | 1 | P11413 | G6PD | More | | Methotrexate | hsa00500 | Starch and sucrose metabolism | 1.54E-03 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Methotrexate | hsa00512 | Mucin type O-glycan biosynthesis | 4.86E-02 | 2 | O95395, Q9NY28 | GCNT3, GALNT8 | More | | Methotrexate | hsa00531 | Glycosaminoglycan degradation | 4.51E-02 | 2 | P22304, P06865 | IDS, HEXA | More | | Methotrexate | hsa00600 | Sphingolipid metabolism | 4.56E-02 | 3 | Q9BX95, Q06136, P06280 | SGPP1, FVT1, GLA | More | | Methotrexate | hsa00630 | Glyoxylate and dicarboxylate metabolism | 9.62E-04 | 3 | P40925, P40926, P15104 | MDH1, MDH2, GLUL | More | | Methotrexate | hsa00670 | One carbon pool by folate | 3.62E-02 | 1 | P00374 | DHFR | More | | Methotrexate | hsa00730 | Thiamine metabolism | 5.29E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Methotrexate | hsa00790 | Folate biosynthesis | 3.62E-02 | 1 | P00374 | DHFR | More | | Methotrexate | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | | Methotrexate | hsa01100 | Metabolic pathways | 1.66E-02 | 31 | Q9Y234, O14521, P15144, Q99707, P11310, P27707, Q13370, P36959, Q13956, P22748, P55809, P06280, P30043, Q02252, O60701, O14772, O95954, Q9HCC0, P33121, P04406, Q96EB6, O15466, P36551, Q9BX95, P09960, Q9P2R7, Q9UHY7, P35573, Q13488, Q16718, Q02809 | LIPT1, SDHD, ANPEP, MTR, ACADM, DCK, PDE3B, GMPR, PDE6H, CA4, OXCT1, GLA, BLVRB, ALDH6A1, UGDH, FPGT, FTCD, MCCC2, ACSL1, GAPDH, SIRT1, ST8SIA5, CPOX, SGPP1, LTA4H, SUCLA2, ENOPH1, AGL, TCIRG1, NDUFA5, PLOD1 | More | | Methotrexate | hsa01200 | Carbon metabolism | 2.91E-02 | 1 | P11413 | G6PD | More | | Methotrexate | hsa01523 | Antifolate resistance | 6.06E-03 | 2 | Q92820, P04818 | GGH, TYMS | More | | Methotrexate | hsa03010 | Ribosome | 1.53E-05 | 8 | P62753, P62906, P46776, Q07020, P61513, P27635, P62249, P23396 | RPS6, RPL10A, RPL27A, RPL18, RPL37A, RPL10, RPS16, RPS3 | More | | Methotrexate | hsa03013 | RNA transport | 2.29E-04 | 12 | O14980, P52298, Q09161, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q14240, Q9Y6A5 | XPO1, NCBP2, NCBP1, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, EIF4A2, TACC3 | More | | Methotrexate | hsa03040 | Spliceosome | 4.48E-04 | 10 | Q14562, O43143, O60508, P17844, P51991, P61978, Q07955, Q01130, Q13243, P11142 | DHX8, DHX15, CDC40, DDX5, HNRPA3, HNRPK, SFRS1, SFRS2, SFRS5, HSPA8 | More | | Methotrexate | hsa03060 | Protein export | 2.43E-02 | 2 | Q15070, O76094 | OXA1L, SRP72 | More | | Methotrexate | hsa04014 | Ras signaling pathway | 8.66E-03 | 7 | Q9NRA1, Q13009, P0DP23, P62873, P63218, P50151, P19174 | PDGFC, TIAM1, CALM1, GNB1, GNG5, GNG10, PLCG1 | More | | Methotrexate | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.79E-02 | 6 | P09341, P25024, P25025, P47992, Q9UBD3, P09603 | CXCL1, CXCR1, CXCR2, XCL1, XCL2, CSF1 | More | | Methotrexate | hsa04062 | Chemokine signaling pathway | 1.10E-04 | 16 | P25024, P25025, P09341, P47992, Q9UBD3, P07948, P19174, P62873, P63218, P50151, Q08881, Q13009, P14598, P42224, P25963, P49841 | CXCR1, CXCR2, CXCL1, XCL1, XCL2, LYN, PLCG1, GNB1, GNG5, GNG10, ITK, TIAM1, NCF1, STAT1, NFKBIA, GSK3B | More | | Methotrexate | hsa04064 | NF-kappa B signaling pathway | 2.83E-02 | 8 | P10415, Q13489, O00463, Q13546, Q9UDY8, Q13077, Q16548, P24522 | BCL2, BIRC3, TRAF5, RIPK1, MALT1, TRAF1, BCL2A1, GADD45A | More | | Methotrexate | hsa04070 | Phosphatidylinositol signaling system | 2.93E-02 | 4 | P19174, P0DP23, P23743, P27987 | PLCG1, CALM1, DGKA, ITPKB | More | | Methotrexate | hsa04071 | Sphingolipid signaling pathway | 5.28E-05 | 9 | P21453, Q9H228, P01375, Q13362, Q16537, Q9BX95, Q16539, P10415, Q9UQC2 | S1PR1, EDG8, TNF, PPP2R5C, PPP2R5E, SGPP1, MAPK14, BCL2, GAB2 | More | | Methotrexate | hsa04072 | Phospholipase D signaling pathway | 3.55E-02 | 4 | Q9UQC2, Q8WYR1, Q15438, P51828 | GAB2, PIK3R5, PSCD1, ADCY7 | More | | Methotrexate | hsa04110 | Cell cycle | 2.34E-02 | 3 | P06493, O60566, P33981 | CDK1, BUB1B, TTK | More | | Methotrexate | hsa04115 | p53 signaling pathway | 3.34E-02 | 2 | P31350, P06493 | RRM2, CDK1 | More | | Methotrexate | hsa04140 | Autophagy - animal | 3.72E-02 | 5 | P22694, Q14643, P10415, Q9H1Y0, Q04759 | PRKACB, ITPR1, BCL2, ATG5, PRKCQ | More | | Methotrexate | hsa04141 | Protein processing in endoplasmic reticulum | 3.12E-05 | 13 | P18848, P30101, Q15437, Q15436, P60604, Q99941, P11142, P07900, P08238, Q9NR31, P14625, Q9H173, Q9UNL2 | ATF4, PDIA3, SEC23B, SEC23A, UBE2G2, CREBL1, HSPA8, HSP90AA1, HSP90AB1, SAR1A, HSP90B1, SIL1, SSR3 | More | | Methotrexate | hsa04142 | Lysosome | 3.32E-03 | 6 | P06865, P22304, Q13510, P07602, P61916, Q04900 | HEXA, IDS, ASAH1, PSAP, NPC2, CD164 | More | | Methotrexate | hsa04145 | Phagosome | 5.53E-04 | 10 | O75015, P11215, Q15075, Q15080, P14598, Q71U36, Q13509, P68371, Q13488, O60603 | FCGR3B, ITGAM, EEA1, NCF4, NCF1, TUBA1A, TUBB3, TUBB2C, TCIRG1, TLR2 | More | | Methotrexate | hsa04151 | PI3K-Akt signaling pathway | 4.12E-04 | 9 | P62753, P27348, P07900, P14625, Q16363, P22105, Q99941, P18848, O00141 | RPS6, YWHAQ, HSP90AA1, HSP90B1, LAMA4, TNXB, CREBL1, ATF4, SGK | More | | Methotrexate | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | | Methotrexate | hsa04211 | Longevity regulating pathway | 2.72E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | | Methotrexate | hsa04213 | Longevity regulating pathway - multiple species | 3.03E-02 | 2 | P51828, P0DMV8 | ADCY7, HSPA1A | More | | Methotrexate | hsa04261 | Adrenergic signaling in cardiomyocytes | 3.65E-04 | 8 | P67936, P51828, Q8WYR1, Q99941, P18848, Q13362, P0DP24, Q13557 | TPM4, ADCY7, PIK3R5, CREBL1, ATF4, PPP2R5C, CALM2, CAMK2D | More | | Methotrexate | hsa04270 | Vascular smooth muscle contraction | 1.86E-02 | 4 | P0DP24, P51828, P35579, P35749 | CALM2, ADCY7, MYH9, MYH11 | More | | Methotrexate | hsa04330 | Notch signaling pathway | 2.93E-02 | 3 | Q13547, Q92769, Q92830 | HDAC1, HDAC2, KAT2A | More | | Methotrexate | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | | Methotrexate | hsa04371 | Apelin signaling pathway | 7.95E-04 | 7 | P62873, P63218, P50151, Q13370, Q14344, P84022, P0DP23 | GNB1, GNG5, GNG10, PDE3B, GNA13, SMAD3, CALM1 | More | | Methotrexate | hsa04540 | Gap junction | 1.08E-02 | 4 | Q13509, P68371, Q71U36, Q9NRA1 | TUBB3, TUBB2C, TUBA1A, PDGFC | More | | Methotrexate | hsa04612 | Antigen processing and presentation | 2.84E-02 | 7 | P13765, P48382, P26715, P26717, Q13241, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | Methotrexate | hsa04613 | Neutrophil extracellular trap formation | 1.38E-03 | 15 | O60603, P05164, P08246, Q9UM07, Q92769, Q6FI13, Q15080, P20160, P08311, P49913, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, HDAC2, H2AC18; H2AC19, NCF4, AZU1, CTSG, CAMP, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Methotrexate | hsa04621 | NOD-like receptor signaling pathway | 3.24E-02 | 9 | Q16539, Q14643, P21796, P10599, P43490, O00463, P29728, P09341, P12838 | MAPK14, ITPR1, VDAC1, TXN, PBEF1, TRAF5, OAS2, CXCL1, DEFA4 | More | | Methotrexate | hsa04623 | Cytosolic DNA-sensing pathway | 2.59E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | | Methotrexate | hsa04640 | Hematopoietic cell lineage | 8.19E-04 | 12 | P13612, P14778, P27930, P15144, P11836, P25063, P07766, P09693, P01732, P13765, P01375, P09603 | ITGA4, IL1R1, IL1R2, ANPEP, MS4A1, CD24, CD3E, CD3G, CD8A, HLA-DOB, TNF, CSF1 | More | | Methotrexate | hsa04650 | Natural killer cell mediated cytotoxicity | 1.77E-02 | 8 | P78314, O60880, P20963, Q13241, P26718, O75015, P26717, P26715 | SH3BP2, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KLRC1 | More | | Methotrexate | hsa04657 | IL-17 signaling pathway | 3.31E-02 | 3 | P49841, P14780, P01375 | GSK3B, MMP9, TNF | More | | Methotrexate | hsa04658 | Th1 and Th2 cell differentiation | 4.11E-04 | 10 | Q04759, P07766, P20963, P09693, Q16539, Q14765, P23771, Q9UL17, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, STAT4, GATA3, TBX21, HLA-DOB, RUNX3 | More | | Methotrexate | hsa04659 | Th17 cell differentiation | 1.27E-03 | 13 | P25963, Q04759, Q16539, P19174, P42224, P14784, P14778, Q9UL17, P84022, P08238, P07766, P09693, P20963 | NFKBIA, PRKCQ, MAPK14, PLCG1, STAT1, IL2RB, IL1R1, TBX21, SMAD3, HSP90AB1, CD3E, CD3G, CD247 | More | | Methotrexate | hsa04660 | T cell receptor signaling pathway | 1.84E-05 | 13 | P01375, Q9UDY8, Q04759, P10747, O95267, Q08881, P07766, P20963, P09693, P01732, Q13191, Q16539, P49841 | TNF, MALT1, PRKCQ, CD28, RASGRP1, ITK, CD3E, CD247, CD3G, CD8A, CBLB, MAPK14, GSK3B | More | | Methotrexate | hsa04664 | Fc epsilon RI signaling pathway | 4.48E-04 | 5 | P04141, P07948, P19174, P09917, P20292 | CSF2, LYN, PLCG1, ALOX5, ALOX5AP | More | | Methotrexate | hsa04668 | TNF signaling pathway | 4.96E-02 | 6 | O00463, Q13546, Q13489, Q16539, Q13077, P14780 | TRAF5, RIPK1, BIRC3, MAPK14, TRAF1, MMP9 | More | | Methotrexate | hsa04672 | Intestinal immune network for IgA production | 1.66E-02 | 3 | P10747, P13765, P13612 | CD28, HLA-DOB, ITGA4 | More | | Methotrexate | hsa04713 | Circadian entrainment | 2.18E-02 | 4 | P0DP23, P62873, P63218, P50151 | CALM1, GNB1, GNG5, GNG10 | More | | Methotrexate | hsa04714 | Thermogenesis | 3.31E-02 | 4 | P51828, P62753, P12074, O15239 | ADCY7, RPS6, COX6A1, NDUFA1 | More | | Methotrexate | hsa04724 | Glutamatergic synapse | 1.57E-02 | 4 | P62873, P63218, P50151, P15104 | GNB1, GNG5, GNG10, GLUL | More | | Methotrexate | hsa04725 | Cholinergic synapse | 2.17E-02 | 3 | P51828, P18848, Q13557 | ADCY7, ATF4, CAMK2D | More | | Methotrexate | hsa04726 | Serotonergic synapse | 3.80E-02 | 4 | P62873, P63218, P50151, P09917 | GNB1, GNG5, GNG10, ALOX5 | More | | Methotrexate | hsa04727 | GABAergic synapse | 4.18E-03 | 4 | P62873, P63218, P50151, P15104 | GNB1, GNG5, GNG10, GLUL | More | | Methotrexate | hsa04728 | Dopaminergic synapse | 4.78E-02 | 3 | Q99941, P18848, Q13557 | CREBL1, ATF4, CAMK2D | More | | Methotrexate | hsa04730 | Long-term depression | 4.86E-02 | 2 | Q14344, P07948 | GNA13, LYN | More | | Methotrexate | hsa04744 | Phototransduction | 9.21E-03 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Methotrexate | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | | Methotrexate | hsa04911 | Insulin secretion | 4.03E-04 | 4 | P51828, Q99941, P18848, Q13557 | ADCY7, CREBL1, ATF4, CAMK2D | More | | Methotrexate | hsa04912 | GnRH signaling pathway | 2.17E-02 | 3 | P51828, P18848, Q13557 | ADCY7, ATF4, CAMK2D | More | | Methotrexate | hsa04915 | Estrogen signaling pathway | 1.02E-04 | 8 | Q99941, P18848, P51828, P07900, P0DMV8, P11142, P0DP24, Q15788 | CREBL1, ATF4, ADCY7, HSP90AA1, HSPA1A, HSPA8, CALM2, NCOA1 | More | | Methotrexate | hsa04918 | Thyroid hormone synthesis | 1.98E-04 | 5 | P51828, Q99941, P18848, P14625, P02768 | ADCY7, CREBL1, ATF4, HSP90B1, ALB | More | | Methotrexate | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | | Methotrexate | hsa04921 | Oxytocin signaling pathway | 2.92E-02 | 4 | P0DP24, P51828, Q96RR4, Q8WYR1 | CALM2, ADCY7, CAMKK2, PIK3R5 | More | | Methotrexate | hsa04924 | Renin secretion | 3.64E-02 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | | Methotrexate | hsa04925 | Aldosterone synthesis and secretion | 1.69E-03 | 4 | Q99941, P18848, P51828, Q13557 | CREBL1, ATF4, ADCY7, CAMK2D | More | | Methotrexate | hsa04926 | Relaxin signaling pathway | 3.34E-02 | 3 | Q99941, P18848, P51828 | CREBL1, ATF4, ADCY7 | More | | Methotrexate | hsa04927 | Cortisol synthesis and secretion | 6.33E-04 | 5 | Q14643, Q99941, P18848, P51828, P22694 | ITPR1, CREBL1, ATF4, ADCY7, PRKACB | More | | Methotrexate | hsa04928 | Parathyroid hormone synthesis, secretion and action | 2.17E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | | Methotrexate | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | | Methotrexate | hsa04934 | Cushing syndrome | 1.12E-03 | 4 | Q99941, P18848, P51828, Q13557 | CREBL1, ATF4, ADCY7, CAMK2D | More | | Methotrexate | hsa04935 | Growth hormone synthesis, secretion and action | 2.72E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | | Methotrexate | hsa04940 | Type I diabetes mellitus | 3.64E-02 | 3 | P10747, P13765, P01375 | CD28, HLA-DOB, TNF | More | | Methotrexate | hsa04962 | Vasopressin-regulated water reabsorption | 2.18E-02 | 2 | P52566, P62491 | ARHGDIB, RAB11A | More | | Methotrexate | hsa04970 | Salivary secretion | 4.92E-02 | 4 | P07550, P22694, Q14643, P49913 | ADRB2, PRKACB, ITPR1, CAMP | More | | Methotrexate | hsa04976 | Bile secretion | 2.44E-02 | 2 | P22694, P08183 | PRKACB, ABCB1 | More | | Methotrexate | hsa05012 | Parkinson disease | 1.77E-02 | 6 | P60604, P19174, P0DP23, Q71U36, Q13509, P68371 | UBE2G2, PLCG1, CALM1, TUBA1A, TUBB3, TUBB2C | More | | Methotrexate | hsa05030 | Cocaine addiction | 4.87E-02 | 2 | Q99941, P18848 | CREBL1, ATF4 | More | | Methotrexate | hsa05031 | Amphetamine addiction | 6.41E-03 | 3 | Q13557, Q99941, P18848 | CAMK2D, CREBL1, ATF4 | More | | Methotrexate | hsa05032 | Morphine addiction | 2.18E-02 | 4 | P62873, P63218, P50151, Q13370 | GNB1, GNG5, GNG10, PDE3B | More | | Methotrexate | hsa05034 | Alcoholism | 2.79E-02 | 2 | P62879, Q9BTM1 | GNB2, H2AFJ | More | | Methotrexate | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.32E-04 | 8 | Q16539, P25963, Q13488, P09341, P19174, P25024, P25025, P07948 | MAPK14, NFKBIA, TCIRG1, CXCL1, PLCG1, CXCR1, CXCR2, LYN | More | | Methotrexate | hsa05130 | Pathogenic Escherichia coli infection | 3.19E-02 | 6 | Q71U36, P16333, Q13509, P68371, Q14344, P25963 | TUBA1A, NCK1, TUBB3, TUBB2C, GNA13, NFKBIA | More | | Methotrexate | hsa05132 | Salmonella infection | 2.75E-02 | 7 | P25963, P08238, O75369, Q71U36, Q13509, P68371, P49754 | NFKBIA, HSP90AB1, FLNB, TUBA1A, TUBB3, TUBB2C, VPS41 | More | | Methotrexate | hsa05134 | Legionellosis | 4.75E-02 | 3 | P25963, P11215, P11142 | NFKBIA, ITGAM, HSPA8 | More | | Methotrexate | hsa05140 | Leishmaniasis | 4.82E-02 | 4 | P14598, P11215, P42224, P25963 | NCF1, ITGAM, STAT1, NFKBIA | More | | Methotrexate | hsa05144 | Malaria | 4.92E-02 | 4 | O60603, P01375, P35443, P26718 | TLR2, TNF, THBS4, KLRK1 | More | | Methotrexate | hsa05145 | Toxoplasmosis | 3.55E-02 | 3 | P23458, Q8WYR1, P0DMV8 | JAK1, PIK3R5, HSPA1A | More | | Methotrexate | hsa05146 | Amoebiasis | 1.48E-02 | 7 | P09341, P27930, P01375, O60603, P05089, P22694, P08311 | CXCL1, IL1R2, TNF, TLR2, ARG1, PRKACB, CTSG | More | | Methotrexate | hsa05161 | Hepatitis B | 3.34E-02 | 3 | Q99941, P18848, P27348 | CREBL1, ATF4, YWHAQ | More | | Methotrexate | hsa05163 | Human cytomegalovirus infection | 1.79E-04 | 14 | P25963, P62873, P63218, P50151, Q14643, P0DP23, Q14344, P49841, P14778, P25025, Q16539, O00463, P30101, P01568 | NFKBIA, GNB1, GNG5, GNG10, ITPR1, CALM1, GNA13, GSK3B, IL1R1, CXCR2, MAPK14, TRAF5, PDIA3, IFNA21 | More | | Methotrexate | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 4.85E-05 | 15 | P01568, P42224, P25963, P49841, P62873, P63218, P50151, P09341, P19174, Q14643, O15123, P07948, Q16539, P04141, P0DP23 | IFNA21, STAT1, NFKBIA, GSK3B, GNB1, GNG5, GNG10, CXCL1, PLCG1, ITPR1, ANGPT2, LYN, MAPK14, CSF2, CALM1 | More | | Methotrexate | hsa05168 | Herpes simplex virus 1 infection | 3.79E-02 | 9 | P25963, P01568, P42224, Q07955, Q01130, Q13243, P30101, Q13398, O75820 | NFKBIA, IFNA21, STAT1, SFRS1, SFRS2, SFRS5, PDIA3, ZNF211, ZNF189 | More | | Methotrexate | hsa05169 | Epstein-Barr virus infection | 1.24E-03 | 13 | Q13547, Q92769, O00463, Q16539, P07948, P30101, Q13761, P24522, P30279, P29728, P07766, P09693, P20963 | HDAC1, HDAC2, TRAF5, MAPK14, LYN, PDIA3, RUNX3, GADD45A, CCND2, OAS2, CD3E, CD3G, CD247 | More | | Methotrexate | hsa05170 | Human immunodeficiency virus 1 infection | 1.19E-02 | 8 | P62873, P63218, P50151, P0DP23, P30101, P01568, P25963, P19174 | GNB1, GNG5, GNG10, CALM1, PDIA3, IFNA21, NFKBIA, PLCG1 | More | | Methotrexate | hsa05171 | Coronavirus disease - COVID-19 | 4.36E-05 | 8 | P23396, P62753, P62249, P62906, P27635, Q07020, P46776, P61513 | RPS3, RPS6, RPS16, RPL10A, RPL10, RPL18, RPL27A, RPL37A | More | | Methotrexate | hsa05200 | Pathways in cancer | 2.14E-04 | 17 | P17301, P08238, P42224, P25963, P19174, P43246, P84022, P20585, P62873, P62879, P63218, P50151, Q14344, O75293, P0DP23, P01568, P14784 | ITGA2, HSP90AB1, STAT1, NFKBIA, PLCG1, MSH2, SMAD3, MSH3, GNB1, GNB2, GNG5, GNG10, GNA13, GADD45B, CALM1, IFNA21, IL2RB | More | | Methotrexate | hsa05202 | Transcriptional misregulation in cancer | 2.85E-04 | 16 | Q15532, P41732, P14780, P27930, Q15744, Q16548, Q13489, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, Q92769, P12980, P24522 | SS18, TSPAN7, MMP9, IL1R2, CEBPE, BCL2A1, BIRC3, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, HDAC2, LYL1, GADD45A | More | | Methotrexate | hsa05203 | Viral carcinogenesis | 1.46E-02 | 4 | Q99941, P18848, P27348, P61978 | CREBL1, ATF4, YWHAQ, HNRPK | More | | Methotrexate | hsa05212 | Pancreatic cancer | 4.75E-02 | 3 | P42224, P84022, O75293 | STAT1, SMAD3, GADD45B | More | | Methotrexate | hsa05214 | Glioma | 4.75E-02 | 3 | P0DP23, P19174, O75293 | CALM1, PLCG1, GADD45B | More | | Methotrexate | hsa05215 | Prostate cancer | 4.48E-02 | 2 | P18848, P14625 | ATF4, HSP90B1 | More | | Methotrexate | hsa05217 | Basal cell carcinoma | 2.01E-02 | 4 | Q13635, P04628, Q9UJU2, P24522 | PTCH1, WNT1, LEF1, GADD45A | More | | Methotrexate | hsa05230 | Central carbon metabolism in cancer | 1.12E-02 | 1 | P11413 | G6PD | More | | Methotrexate | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 3.65E-02 | 6 | O95267, P07766, P20963, P09693, Q04759, Q16539 | RASGRP1, CD3E, CD247, CD3G, PRKCQ, MAPK14 | More | | Methotrexate | hsa05310 | Asthma | 1.66E-02 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Methotrexate | hsa05321 | Inflammatory bowel disease | 1.14E-03 | 6 | O60603, P01375, P13765, Q14765, Q9UL17, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3 | More | | Methotrexate | hsa05323 | Rheumatoid arthritis | 1.58E-02 | 5 | P01375, P13765, P10747, P09341, O60603 | TNF, HLA-DOB, CD28, CXCL1, TLR2 | More | | Methotrexate | hsa05332 | Graft-versus-host disease | 2.03E-03 | 5 | P13765, P10747, P01375, P26715, Q13241 | HLA-DOB, CD28, TNF, KLRC1, KLRD1 | More | | Methotrexate | hsa05415 | Diabetic cardiomyopathy | 3.59E-02 | 1 | P11413 | G6PD | More | | |